Skip to main content
LISATA THERAPEUTICS, INC. logo

LISATA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LSTA ISIN · US1280583022 LEI · 5493002287F62M3EGQ04 US Manufacturing
Open in API
Filings indexed 1,093 across all filing types
Latest filing 2025-11-06 Interim / Quarterly Rep…
Country US United States of America
Listing US LSTA

About LISATA THERAPEUTICS, INC.

https://www.lisata.com/

Lisata Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for advanced solid tumors and other major diseases. The company's core technology is the proprietary CendR Platform®, designed to enhance the targeted, tissue-penetrating delivery of anti-cancer drugs to solid tumors. The platform also aims to target non-cancerous, immunosuppressive cells within the tumor microenvironment, seeking to improve the efficacy of a patient's immune system and immunotherapies in fighting cancer.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report 9M 2025
2025-11-06 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 6, 2025, by Lisata Therapeutics, Inc. It includes a press release about financial results for the third quarter ended September 30, 2025, and a corporate presentation. The document states that the press release and presentation are furnished as exhibits and incorporated by reference. The length is 4028 characters, which is relatively short and typical for an 8-K filing announcing earnings results and related materials. The document does not contain detailed financial statements or substantive financial data itself but rather references and attaches a press release and presentation. This matches the characteristics of an Earnings Release (ER) announcement rather than a full Interim/Quarterly Report (IR) or Annual Report (10-K). Therefore, the appropriate classification is Earnings Release (ER).
2025-11-06 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Lisata Therapeutics, Inc. The key content is the disclosure of a slide presentation used at investor and industry conferences, attached as Exhibit 99.1. The document explicitly states that the presentation is being furnished under Item 7.01 Regulation FD Disclosure and is not considered "filed" for certain legal purposes. The document does not contain financial statements or detailed financial analysis but rather a presentation for investors. Given the nature of the content (a corporate presentation for investors) and the context (Item 7.01 Regulation FD Disclosure), the most appropriate classification is Investor Presentation (IP). The document length is 3604 characters, which is consistent with a brief report announcing or including a presentation rather than a full financial report. Therefore, the filing type code is IP with high confidence.
2025-10-14 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 8, 2025, by Lisata Therapeutics, Inc. It reports the entry into a material definitive agreement, specifically a Non-Exclusive License Agreement with Catalent, Inc. The content focuses on the terms of the agreement, financial terms, termination rights, and rights of first negotiation. There are no financial statements or quarterly/yearly financial results presented. The document is a current report disclosing a significant corporate event related to licensing and partnership, which fits the category of Capital/Financing Update (CAP) as it involves licensing agreements and potential revenue sharing impacting the company's capital structure and future income. It is not an Annual Report, Earnings Release, or Management Report. It is not a regulatory filing of miscellaneous nature (RNS) because it specifically reports a material definitive agreement. Therefore, the best classification is CAP with high confidence.
2025-10-08 English
10-Q
Interim / Quarterly Report Q2 2025
2025-08-07 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 7, 2025, by Lisata Therapeutics, Inc. It includes a press release about financial results for the second quarter ended June 30, 2025, and a corporate presentation. The document states that the press release and presentation are furnished as exhibits and incorporated by reference, and the information is being furnished, not filed. The length is 4014 characters, which is relatively short and the document primarily announces the availability of financial results and a presentation rather than containing the full financial report itself. This fits the pattern of a Regulatory Filing (RNS) as it is a current report disclosing material events but not a full earnings release or interim report. The presence of a press release and presentation as exhibits supports this classification rather than classifying it as an Earnings Release (ER) or Interim Report (IR). Therefore, the best classification is Regulatory Filings (RNS).
2025-08-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.